The pharmacological management of ovulatory dysfunction spans a spectrum from low-complexity oral agents used in anovulatory women with polycystic ovary syndrome (PCOS) to the highly controlled gonadotropin protocols used in assisted reproductive technology (ART). A precise understanding of the mechanisms that distinguish clomiphene citrate from letrozole, the biological differences among available gonadotropin preparations, the pharmacological role of human chorionic gonadotropin (hCG) as a surrogate luteinizing hormone (LH) surge, and the protocol design logic of ART stimulation cycles provides the foundation for understanding both clinical decision-making and the pathophysiology of ovarian hyperstimulation syndrome (OHSS). OHSS is the most serious iatrogenic complication of ovarian stimulation, and its prevention and management depend directly on understanding how each pharmacological intervention in the stimulation cycle modifies OHSS risk.
Clomiphene citrate (CC) is a non-steroidal triphenylethylene derivative with mixed estrogen receptor (ER) agonist and antagonist properties that has been the first-line oral ovulation induction agent for anovulatory women since the 1960s. Its primary mechanism of ovulation induction is blockade of hypothalamic ERα, which prevents negative feedback from circulating estradiol on the hypothalamic-pituitary axis. Under normal estrogenic feedback, hypothalamic kisspeptin neuron-mediated gonadotropin-releasing hormone (GnRH) pulse frequency is suppressed by estradiol binding to ERα in kisspeptin neurons; clomiphene occupies ERα and prevents this feedback signal, producing a perceived estrogen-deficient state at the hypothalamus and driving a compensatory increase in GnRH pulse frequency and amplitude. The resulting rise in follicle-stimulating hormone (FSH) recruits and drives follicular development in women with intact hypothalamic-pituitary-ovarian (HPO) axis function whose anovulation arises from inadequate tonic FSH drive rather than primary gonadotropin deficiency.1
Clomiphene is administered orally at doses of 50 to 150 mg per day for 5 days beginning on cycle days 2 through 5. The drug is a racemic mixture of two geometric isomers: enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). Enclomiphene has predominantly antagonist activity and a shorter half-life (approximately 5 to 7 days), while zuclomiphene is a longer-acting partial agonist (half-life approximately 2 weeks) that accumulates with repeated cycles and contributes to the dose-dependent anti-estrogenic side effects. Ovulation is achieved in approximately 80% of appropriately selected women, but live birth rates per cycle are substantially lower at approximately 22% to 35% because anti-estrogenic effects of clomiphene extend beyond the hypothalamus to the endometrium (producing thin, poorly proliferating endometrium) and to the cervix (producing viscous, hostile cervical mucus that impairs sperm penetration). These peripheral anti-estrogenic effects represent a pharmacological paradox: the same receptor blockade that restores FSH secretion simultaneously impairs the uterine and cervical environment necessary for fertilization and implantation.1
Letrozole, an aromatase inhibitor (AI) of the triazole class originally developed for postmenopausal breast cancer treatment, has supplanted clomiphene as the preferred first-line ovulation induction agent for women with polycystic ovary syndrome (PCOS), based on superior live birth rates in the landmark National Institute of Child Health and Human Development (NICHD) Cooperative Reproductive Medicine Network trial comparing letrozole to clomiphene in 750 women with PCOS.2 Letrozole competitively inhibits cytochrome P450 19A1 (CYP19A1), the aromatase enzyme complex responsible for the conversion of androgens (androstenedione and testosterone) to estrogens (estrone and estradiol) in ovarian granulosa cells and peripheral adipose tissue. By reducing estradiol production, letrozole creates a transient hypoestrogen state3 that removes negative feedback from the hypothalamic-pituitary axis and causes a compensatory FSH rise, recruiting follicular development through a mechanism analogous to clomiphene but through a distinct pharmacological route: estrogen biosynthesis inhibition rather than receptor blockade.23
The key pharmacological advantages of letrozole over clomiphene in ovulation induction derive from its mechanism: because letrozole reduces estrogen production rather than occupying ER, estrogen receptors throughout the body remain free to respond to whatever estradiol is produced by the developing follicle(s). Once follicular development is stimulated and the developing follicle begins producing estradiol, the estradiol can exert its normal estrogenic effects on the endometrium, cervical mucus, and pituitary, producing physiologically superior endometrial proliferation and cervical mucus permeability compared to clomiphene-treated cycles. The letrozole drug itself is cleared rapidly (half-life approximately 45 hours), so by the time follicular growth is established and estradiol rises, letrozole is largely eliminated and its inhibitory effect has dissipated, allowing the rising estradiol to act on a native ER-intact reproductive tract. This mechanism also explains why letrozole produces predominantly monofollicular ovulation with a multiple gestation rate of approximately 3% to 7%, lower than the 8% to 13% multiple gestation rate of clomiphene, because the negative feedback loop remains intact through native ER signaling once letrozole is cleared.23
The 2014 NICHD trial (Legro et al., NEJM) randomized 750 women with PCOS to letrozole 2.5 mg vs clomiphene 50 mg (days 3–7) for up to 5 cycles. Letrozole produced a significantly higher live birth rate (27.5% vs 19.1%), higher ovulation rate, and lower multiple gestation rate than clomiphene. The superior live birth rate with letrozole reflects both better ovulation rates and the absence of anti-estrogenic endometrial and cervical effects. Letrozole is used off-label for this indication in the USA (not formally approved for ovulation induction) but is standard of care per ASRM guidelines.
Exogenous gonadotropins directly supply the pituitary hormones follicle-stimulating hormone (FSH) and luteinizing hormone (LH) to the ovary, bypassing the hypothalamic-pituitary axis entirely and allowing direct control of follicular development independent of endogenous hormonal status. Gonadotropin preparations are used when oral ovulation induction agents fail, in women with hypothalamic amenorrhea or hypogonadotropic hypogonadism (WHO Group I anovulation, where both FSH and LH are deficient), and as the core pharmacological component of all controlled ovarian stimulation (COS) protocols in assisted reproductive technology (ART). The available preparations differ in their source (urinary-derived vs recombinant), gonadotropin content (FSH-only vs FSH+LH), degree of LH activity, and glycosylation profiles that affect pharmacokinetics and receptor binding properties.4
Urinary-derived gonadotropins are extracted and purified from the urine of postmenopausal women, which contains high concentrations of FSH and LH due to the absence of ovarian feedback in menopause. Human menopausal gonadotropin (hMG, also known as menotropins), the original gonadotropin preparation, contains approximately equal proportions of FSH and LH activity (75 international units [IU] of each per ampoule in most formulations), with hCG contributing most of the measured LH bioactivity in standard hMG preparations because immunological cross-reactivity between LH and hCG means that urinary hCG from reproductive-age donors contaminating postmenopausal urine can be measured as LH. Highly purified FSH (urofollitropin HP) preparations are urinary-derived FSH with the LH and non-gonadotropin proteins removed to greater than 95% purity, allowing injection volumes suitable for subcutaneous administration. The key pharmacological difference between hMG and FSH-only preparations is the presence or absence of LH activity, which becomes clinically relevant in women with hypogonadotropic hypogonadism, who require both FSH and LH to achieve adequate follicular development and estradiol production because granulosa cells require LH-stimulated theca cell androgen production as the substrate for FSH-driven aromatization.4
Recombinant gonadotropins are produced through expression of the respective glycoprotein subunit genes in Chinese hamster ovary (CHO) cell lines, producing highly consistent, batch-to-batch reproducible preparations with defined potency. Recombinant FSH (follitropin alfa, follitropin beta, corifollitropin alfa) contains only FSH with no LH contamination, allowing precise FSH dosing without variable LH co-administration. Recombinant LH (lutropin alfa) is available as a standalone preparation to supplement recombinant FSH in women with hypogonadotropic hypogonadism or in ART cycles where supplemental LH activity is desired. Recombinant hCG (choriogonadotropin alfa) is used for triggering ovulation. Corifollitropin alfa is a long-acting recombinant FSH fused with the carboxy-terminal peptide (CTP) of the hCG beta subunit, extending the half-life from approximately 24 hours for standard FSH to approximately 65 to 70 hours, allowing a single injection to maintain stimulatory FSH levels for the first 7 days of a stimulation cycle and eliminating the need for daily FSH injections during the early follicular phase.5
The clinical choice between urinary-derived and recombinant FSH preparations has been extensively studied in randomized trials and meta-analyses. For ART outcomes, recombinant FSH produces marginally higher oocyte yields per stimulation cycle but no statistically significant difference in live birth rates per started cycle compared to urinary-derived FSH in most meta-analyses. The clinically significant distinction for most ART patients is therefore convenience (recombinant preparations allow subcutaneous self-administration with a prefilled pen device versus the intramuscular injection required for many urinary preparations), cost (urinary preparations are substantially less expensive in most health systems), and local availability. For women with WHO Group I hypogonadotropic hypogonadism, hMG or recombinant FSH plus recombinant LH is required because FSH alone is insufficient without LH-driven theca cell androgen substrate; for all other anovulatory women and for COS in normgonadotropic women, FSH-only preparations are appropriate.4
The two-cell, two-gonadotropin model of follicular steroidogenesis requires LH to drive theca cell production of androstenedione and testosterone, which diffuse to granulosa cells and serve as substrate for FSH-driven CYP19A1 (aromatase)-mediated conversion to estrone and estradiol. In women with hypogonadotropic hypogonadism (WHO Group I), endogenous LH is absent or minimal, meaning FSH alone cannot produce adequate estradiol because the androgen substrate is insufficient. This pharmacological principle is the basis for the combination approach: recombinant FSH plus recombinant LH, or hMG (which contains LH/hCG activity), is required for effective induction in this population.
Human chorionic gonadotropin (hCG) is a glycoprotein hormone produced by the syncytiotrophoblast of the implanting embryo and the developing placenta, where it functions to rescue the corpus luteum from luteal regression and sustain progesterone production during early pregnancy. Its structural homology with luteinizing hormone (LH) is high: both share an identical alpha subunit (with follicle-stimulating hormone [FSH] and thyroid-stimulating hormone [TSH]) and have closely related beta subunits that share approximately 85% amino acid sequence homology in the receptor-binding region.6 This structural similarity allows hCG to bind and activate the LH receptor (LHR) with high affinity, and this cross-reactivity is the pharmacological basis for using hCG as an LH surrogate to trigger the final oocyte maturation step in ovulation induction and assisted reproductive technology (ART) cycles.6
In natural cycles, the mid-cycle LH surge triggers a cascade of events in the pre-ovulatory follicle: resumption of oocyte meiosis from prophase I arrest, expansion of the cumulus oophorus, follicular wall remodeling, and ultimately follicular rupture approximately 34 to 36 hours after the onset of the LH surge. In ovulation induction and ART cycles, follicular rupture does not occur spontaneously because exogenous gonadotropins have suppressed endogenous LH, and the triggering agent must be administered at the appropriate time to replicate the LH surge. Urinary hCG (u-hCG, derived from the urine of pregnant women) at doses of 5,000 to 10,000 international units (IU) or recombinant hCG (r-hCG, choriogonadotropin alfa) at 250 micrograms are the standard trigger agents, with oocyte retrieval timed at 34 to 36 hours after the trigger injection. The key pharmacological distinction between hCG and native LH is duration of action: hCG has a serum half-life of approximately 24 to 36 hours compared to approximately 60 minutes for LH, meaning that hCG produces sustained LHR stimulation for 5 to 7 days, which is the pharmacological basis for both its utility in luteal support and its role in precipitating ovarian hyperstimulation syndrome (OHSS).7
In fresh embryo transfer cycles, the supraphysiological gonadotropin stimulation used for oocyte retrieval produces multiple corpora lutea that generate high progesterone and estradiol levels, but concurrent GnRH agonist or antagonist co-administration for pituitary suppression (discussed in Section 4) impairs endogenous LH secretion in the post-retrieval luteal phase, creating luteal phase deficiency. Progesterone supplementation is therefore mandatory in all fresh ART cycles to support the endometrium and early pregnancy: oral micronized progesterone (typically 200 to 600 mg per day vaginally, as vaginal bioavailability produces higher endometrial progesterone concentrations than oral use), intramuscular progesterone-in-oil (typically 50 mg per day), or subcutaneous progesterone are all used, with vaginal administration preferred in most protocols for its superior uterine first-pass delivery and avoidance of the pain, local reactions, and oil-embolism risk associated with intramuscular oil-based injections. Luteal support is maintained from the day of embryo transfer until a positive pregnancy test and typically continued to 8 to 12 weeks of gestation if pregnancy is confirmed, at which time placental progesterone production is sufficient for independent support.7
GnRH agonist triggering represents a critical advance in OHSS prevention available in antagonist-protocol cycles. Rather than hCG, a single dose of a GnRH agonist (such as triptorelin or buserelin) is administered at the time follicles are mature to trigger an endogenous LH surge from the pituitary. This approach is possible only in antagonist cycles because the pituitary remains responsive to GnRH stimulation (not yet downregulated), whereas in long agonist-protocol cycles the pituitary has already been fully downregulated and cannot produce an LH surge in response to additional GnRH agonist. The endogenous LH surge produced by GnRH agonist triggering is shorter in duration than the prolonged hCG-mediated LHR stimulation, substantially reducing luteotropic stimulation of the multiple corpora lutea and dramatically lowering OHSS risk. The trade-off is a compromised luteal phase requiring intensive luteal support or elective freeze-all of embryos for subsequent frozen embryo transfer, in which the endogenous uterine environment is restored by a hormone replacement protocol rather than relying on the deficient natural luteal phase.78
In antagonist cycles, substituting GnRH agonist for hCG as the ovulation trigger eliminates severe OHSS in virtually all patients by producing a brief LH surge rather than sustained LHR stimulation. The compromise: the luteal phase is inadequate even with standard progesterone supplementation, resulting in lower pregnancy rates in fresh transfer cycles. The clinical solution for high-OHSS-risk patients is a GnRH agonist trigger followed by a freeze-all strategy: all embryos are vitrified and transferred in a subsequent frozen embryo transfer cycle under a hormone replacement protocol, combining maximal OHSS prevention with preserved cumulative pregnancy rates.
Controlled ovarian stimulation (COS) for assisted reproductive technology (ART) requires simultaneous achievement of multiple mature follicles while preventing premature endogenous luteinizing hormone (LH) surges that would trigger ovulation before oocyte retrieval can be performed. The pharmacological challenge is therefore twofold: provide exogenous follicle-stimulating hormone (FSH) to drive multiple follicular development beyond the normal one-follicle-per-cycle selection, and prevent the rising estradiol from the multiple developing follicles from triggering a premature LH surge through positive feedback at the pituitary. Two principal pituitary suppression strategies have been developed, each with distinct pharmacological mechanisms, protocol structures, timing requirements, and ovarian hyperstimulation syndrome (OHSS) risk profiles.59
The long GnRH agonist protocol (also called the long down-regulation protocol) uses a GnRH agonist initiated in the mid-luteal phase of the preceding cycle or at the start of the menstrual cycle. The agonist is administered continuously until pituitary downregulation is achieved (typically 10 to 14 days), confirmed by suppressed serum estradiol below 50 to 80 picograms per milliliter and absence of ovarian cysts on ultrasound. Once downregulation is confirmed, FSH stimulation begins while the GnRH agonist is continued at a lower maintenance dose throughout the stimulation phase to prevent premature LH recovery. This protocol uses the paradoxical suppression mechanism of GnRH agonists (receptor downregulation, as detailed in Ova-03) to create a controlled pituitary environment in which the timing of ovarian events is governed entirely by exogenous FSH administration and hCG triggering. The long agonist protocol produces excellent synchrony of follicular development and high oocyte yield but requires a longer treatment duration (approximately 4 to 6 weeks total), carries a higher risk of OHSS in high-responder patients due to the sustained pituitary suppression preventing any LH feedback, and is associated with a longer recovery period and higher medication requirements.59
The GnRH antagonist protocol administers GnRH antagonist only during the mid-to-late follicular phase, after ovarian stimulation with exogenous FSH has already begun. The antagonist is introduced when the leading follicle reaches approximately 13 to 14 mm diameter or when serum estradiol rises above a threshold that poses LH surge risk, typically on day 5 to 6 of FSH stimulation. Because antagonists produce immediate competitive receptor blockade without the initial stimulatory flare of agonists, they can be introduced mid-stimulation without causing the gonadotropin surge that would preclude agonist use at the same time point. The antagonist protocol is shorter (approximately 10 to 14 days total), requires fewer injections, avoids the prolonged downregulation phase, and it enables GnRH agonist triggering at the end of stimulation to prevent OHSS. The antagonist protocol has largely supplanted the long agonist protocol in high-risk and normal-responder patients across most modern ART programs because of its shorter, more patient-friendly timeline and superior OHSS prevention capacity.9
Individualized FSH dosing is informed by ovarian reserve markers: anti-Mullerian hormone (AMH) and antral follicle count (AFC) by transvaginal ultrasound predict the likely ovarian response to a given FSH dose. Women with low AMH (below 0.5 to 1.0 ng/mL) or low AFC (below 5 to 7 antral follicles) are poor responders who may require higher FSH doses (300 to 450 IU per day) and may still produce fewer than the optimal number of oocytes; women with high AMH (above 3.0 ng/mL) or high AFC are high-responders or likely polycystic ovary syndrome (PCOS) patients who should receive low starting FSH doses (75 to 100 IU per day) and be managed with strategies to minimize OHSS risk. Minimal stimulation ART uses gonadotropins at very low doses (37.5 to 75 IU per day) or combines clomiphene with low-dose FSH to produce a smaller number of oocytes (typically 1 to 3) with greatly reduced OHSS risk and lower costs, accepting reduced oocyte yield for a more tolerable and less expensive treatment course suitable for poor responders and patients who decline standard stimulation.9
Antagonist protocol preferred for: high OHSS risk (high AMH, PCOS, prior OHSS), patients who want GnRH agonist trigger for OHSS elimination, patient preference for shorter protocol, most standard-responder patients today. Long agonist protocol preferred for: patients with prior poor response to antagonist cycles, specific clinical situations requiring deep pituitary suppression, and some programs where synchrony advantages outweigh the risk-benefit trade-offs for specific patient subgroups. AMH and AFC should guide starting FSH dose in all protocols.
Ovarian hyperstimulation syndrome (OHSS) is an iatrogenic, potentially life-threatening complication of ovarian stimulation characterized by bilateral ovarian enlargement, third-space fluid accumulation (ascites, pleural and pericardial effusions), hemoconcentration, and in severe cases, thromboembolism, renal impairment, and hepatic dysfunction. The syndrome does not occur without exogenous gonadotropin stimulation and, in the context of assisted reproductive technology (ART), is overwhelmingly triggered by hCG administration, either as the ovulation trigger or from the rising hCG of early pregnancy. Understanding OHSS pathophysiology requires understanding why hCG, and not follicle-stimulating hormone (FSH) or even the luteinizing hormone (LH) surge, is the principal precipitating signal, and why high ovarian responsiveness creates the biologically amplified substrate on which hCG acts to produce the syndrome.810
The central mediator of OHSS vascular pathophysiology is vascular endothelial growth factor A (VEGF-A), produced in supraphysiological quantities by the luteinized granulosa cells of multiple stimulated corpora lutea and large pre-ovulatory follicles. VEGF-A binds kinase insert domain receptor (VEGFR2, also known as KDR) on the endothelium of ovarian vessels and peritoneal capillaries, activating downstream signaling pathways that increase vascular permeability by disrupting endothelial tight junctions. This permeability increase allows protein-rich plasma to extravasate from the intravascular compartment into the peritoneal cavity and other third spaces, producing ascites while simultaneously reducing intravascular oncotic pressure and plasma volume. The resulting intravascular hypovolemia stimulates the renin-angiotensin-aldosterone system (RAAS), causing sodium and water retention that fails to correct the effective hypovolemia because retained fluid continues to leak into third spaces rather than remaining intravascular. Hemoconcentration (elevated hematocrit and hemoglobin), reduced urine output, electrolyte disturbances, and impaired organ perfusion follow in severe cases.8
hCG drives OHSS by providing potent, sustained LH receptor stimulation to the luteinized granulosa cells of multiple stimulated corpora lutea, dramatically amplifying VEGF production beyond what the natural LH surge would produce in a single corpus luteum. In stimulated cycles without hCG triggering, even high levels of endogenous LH produce limited OHSS because the LH signal is transient (LH half-life approximately 60 minutes). The prolonged LH receptor (LHR) stimulation from exogenous hCG (half-life 24 to 36 hours for u-hCG, producing detectable activity for 5 to 7 days) sustains VEGF secretion from multiple corpora lutea for the full post-trigger period. When pregnancy occurs in a stimulated cycle, rising endogenous hCG from the implanting embryo provides a second wave of LHR stimulation beginning approximately 7 to 10 days after retrieval, producing the late-onset OHSS that begins around week 4 to 6 of pregnancy and is typically more prolonged and more severe than the early-onset OHSS that follows the trigger injection.810
Patient-level OHSS risk factors reflect the biological conditions that amplify the VEGF response to hCG stimulation. High ovarian reserve as measured by elevated AMH (above 3.0 to 3.5 ng/mL) or high AFC (above 15 to 20 antral follicles) identifies women with large numbers of FSH-sensitive follicles that will respond to stimulation with the recruitment of multiple cohorts and produce a large number of corpora lutea after triggering. Polycystic ovary syndrome (PCOS), in which both AFC and AMH are characteristically elevated, is the strongest clinical risk factor for OHSS and should trigger proactive OHSS-prevention protocol modifications. A prior history of OHSS is the single strongest historical risk factor and predicts recurrence in subsequent cycles unless protocol changes are made. Low body weight (body mass index [BMI] below 18 to 20 kg/m²), young age (below 30 to 35 years), and retrieved oocyte count above 15 to 20 in a given cycle also independently predict higher OHSS risk. Peak estradiol above 3,000 to 4,000 picograms per milliliter on the day of triggering and a large number of pre-ovulatory follicles above 14 to 16 mm on trigger day are cycle-specific risk factors that can be assessed prospectively to guide the trigger decision.10
Early OHSS begins within 3 to 9 days of the hCG trigger injection and typically resolves within 7 to 10 days if pregnancy does not occur. Late OHSS begins 10 or more days after trigger (or around day 4 to 6 of pregnancy) and is driven by rising endogenous hCG from the implanting embryo, making it more prolonged, more severe on average, and potentially dangerous throughout the first trimester. The freeze-all strategy prevents late OHSS entirely by deferring embryo transfer to a subsequent cycle when the stimulated ovaries have recovered: the fresh cycle produces and cryopreserves embryos, and transfer occurs weeks to months later in a hormonally prepared frozen embryo transfer cycle without stimulation.
Ovarian hyperstimulation syndrome (OHSS) is classified by severity based on clinical and laboratory features.11 Mild OHSS encompasses ovarian enlargement up to 8 cm with abdominal bloating, nausea, and mild discomfort; the patient is ambulatory and requires no intervention beyond oral hydration and analgesics, with close outpatient monitoring. Moderate OHSS involves ovarian enlargement of 8 to 12 cm, ultrasound-visible ascites, moderate abdominal pain, and vomiting, with hematocrit below 45% and normal renal function; outpatient management with daily weight monitoring, fluid intake tracking, and close telephone or clinic contact is appropriate. Severe OHSS is defined by clinical ascites, large ovarian size above 12 cm, hematocrit above 45%, leukocytosis above 15,000 cells per microliter, markedly reduced urine output (below 1 mL/kg per hour or below 600 mL per day), creatinine elevation, or hepatic dysfunction, and typically requires inpatient management, intravenous hydration, paracentesis for tense ascites, anticoagulation, and close monitoring of fluid balance and organ function. Critical OHSS adds features of acute respiratory distress syndrome (ARDS), thromboembolism, renal failure, or pericardial effusion requiring intensive care unit (ICU) admission.1011
Pharmacological prevention of OHSS begins at the protocol design level. Proactive low-dose follicle-stimulating hormone (FSH) protocols (beginning at 75 to 100 international units (IU) per day in high-AMH women with polycystic ovary syndrome (PCOS)) limit the number of recruited follicles and corpora lutea. The single most impactful pharmacological intervention for OHSS prevention is the substitution of GnRH agonist triggering for hCG triggering in antagonist-protocol cycles, which reduces severe OHSS rates from approximately 1% to 2% with hCG trigger to near zero with agonist trigger in high-risk patients, at the cost of a compromised luteal phase requiring either intensive luteal support or a freeze-all strategy. Cabergoline, a dopamine type 2 (D2) receptor agonist, reduces vascular endothelial growth factor (VEGF)-driven vascular permeability through activation of VEGF receptor 2 (VEGFR2) phosphorylation inhibition: cabergoline at 0.5 mg per day for 8 days beginning on the day of oocyte trigger significantly reduces the incidence and severity of early OHSS12 in high-risk women without impairing pregnancy rates, and is recommended in current guidelines as adjunctive prophylaxis in high-OHSS-risk patients undergoing hCG triggering. The mechanism involves dopamine receptor activation on endothelial cells modulating VEGFR2 signaling downstream of VEGF-A [VEGF type A] binding, reducing the permeability increase that drives ascites formation.12
Intravenous albumin infusion at the time of oocyte retrieval has been used as an OHSS prevention strategy in high-risk patients by raising colloid oncotic pressure in the immediate post-retrieval period, theoretically limiting the initial extravasation of protein-rich plasma into third spaces. Meta-analyses of albumin infusion as OHSS prophylaxis show a modest reduction in OHSS incidence but not severity, and its routine use has been questioned given the high cost of albumin, the limited magnitude of benefit, and the availability of the far more effective GnRH agonist trigger strategy in antagonist cycles. Intravenous hydroxyethyl starch (HES) as an alternative colloid for volume expansion was used in some programs but has largely been abandoned due to safety concerns about HES-induced coagulopathy with repeated or high-dose use. Current practice in most programs favors the GnRH agonist trigger plus freeze-all strategy as the standard OHSS prevention protocol for high-risk patients, with cabergoline as adjunctive prophylaxis when some hCG luteotropic activity is preserved for luteal support purposes.811
Active OHSS management targets the pathophysiological consequences of plasma extravasation and intravascular hypovolemia. Intravenous crystalloid resuscitation corrects the hypovolemia but must be administered carefully to avoid fluid overload in a patient who is already distributing fluid into third spaces; isotonic saline or balanced crystalloid is preferred over hypotonic solutions, which would worsen hypo-osmolality. In moderate to severe OHSS with tense ascites, ultrasound-guided paracentesis relieves abdominal discomfort, improves diaphragmatic excursion and respiratory function, and removes the protein-rich ascitic fluid that is drawing further intravascular fluid into the peritoneum; paracentesis can be performed transvaginally or transabdominally and may need to be repeated. Anticoagulation with low-molecular-weight heparin (LMWH) is recommended for hospitalized OHSS patients because the combination of hemoconcentration, immobility, and the prothrombotic hormonal environment of early pregnancy creates a significant venous thromboembolism risk; thromboembolism is a leading cause of OHSS-related mortality. Elective dopamine infusion at low (renal-protective) doses has been used to improve renal perfusion and urine output in oliguric OHSS patients, though evidence for this practice is limited to small series and expert opinion.1011
Cabergoline's OHSS-preventive mechanism operates at the level of VEGFR2 signaling: dopamine D2 receptor activation on endothelial cells phosphorylates VEGFR2 on a different tyrosine residue than VEGF-A binding, impairing VEGFR2 internalization and the downstream permeability-increasing signaling cascade. This represents a pharmacological interference with VEGF-A signaling at the receptor level rather than blocking VEGF-A production. Cabergoline does not reduce VEGF levels; it modulates the receptor's response to VEGF, providing an adjunct to GnRH agonist triggering in patients where some luteotropic support is needed or where the freeze-all strategy is not pursued.
Adashi EY. Clomiphene citrate: mechanism(s) and site(s) of action — a hypothesis revisited. Fertil Steril. 1984;42(3):331–344.
doi:10.1016/s0015-0282(16)48078-3Legro RS, Brzyski RG, Diamond MP, et al; NICHD Reproductive Medicine Network. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371(2):119–129.
doi:10.1056/NEJMoa1313517Mitwally MF, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75(2):305–309.
doi:10.1016/s0015-0282(00)01705-2Balen AH, Platteau P, Andersen AN, et al. The influence of body weight on response to ovulation induction with gonadotrophins in 335 women with World Health Organization Group II anovulatory infertility. BJOG. 2006;113(10):1195–1202.
doi:10.1111/j.1471-0528.2006.01034.xDevroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first 7 days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063–3072.
doi:10.1093/humrep/dep291Miyamoto K, Hasegawa Y, Igarashi M, et al. Identification of the second gonadotropin-releasing hormone in chicken hypothalamus: evidence that gonadotropin secretion is probably controlled by two distinct gonadotropin-releasing hormones in avian species. Proc Natl Acad Sci USA. 1984;81(12):3874–3878.
doi:10.1073/pnas.81.12.3874van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154.
doi:10.1002/14651858.CD009154.pub3Humaidan P, Quartarolo J, Papanikolaou EG. Preventing ovarian hyperstimulation syndrome: guidance for the clinician. Fertil Steril. 2010;94(2):389–400.
doi:10.1016/j.fertnstert.2010.03.028Fauser BC, Diedrich K, Devroey P; Evian Annual Reproduction Workshop Group 2007. Predictors of ovarian response: progress towards individualized treatment in ovulation induction and ovarian stimulation. Hum Reprod Update. 2008;14(1):1–14.
doi:10.1093/humupd/dmm034Delvigne A, Rozenberg S. Systematic review of data concerning etiopathology of ovarian hyperstimulation syndrome. Int J Fertil Womens Med. 2002;47(5):211–226. PMID: 12398226.
Royal College of Obstetricians and Gynaecologists. Ovarian Hyperstimulation Syndrome: Green-top Guideline No. 5. RCOG Press; 2016. Available at: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/ovarian-hyperstimulation-syndrome-green-top-guideline-no-5/
Alvarez C, Marti-Bonmati L, Novella-Maestre E, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92(8):2931–2937.
doi:10.1210/jc.2007-0409